Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

KalVista Pharmaceuticals (KALV) Gains from Investment Securities (2017 - 2025)

KalVista Pharmaceuticals' Gains from Investment Securities history spans 7 years, with the latest figure at $1.3 million for Q2 2025.

  • For Q2 2025, Gains from Investment Securities rose 563.59% year-over-year to $1.3 million; the TTM value through Apr 2025 reached $2.5 million, up 85.28%, while the annual FY2025 figure was $1.6 million, 17.81% up from the prior year.
  • Gains from Investment Securities for Q2 2025 was $1.3 million at KalVista Pharmaceuticals, up from $649000.0 in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $1.3 million in Q2 2025 and bottomed at $195000.0 in Q2 2024.
  • The 3-year median for Gains from Investment Securities is $317000.0 (2024), against an average of $512142.9.
  • The largest annual shift saw Gains from Investment Securities rose 0.96% in 2024 before it skyrocketed 563.59% in 2025.
  • A 3-year view of Gains from Investment Securities shows it stood at $595000.0 in 2023, then increased by 9.08% to $649000.0 in 2024, then surged by 99.38% to $1.3 million in 2025.
  • Per Business Quant, the three most recent readings for KALV's Gains from Investment Securities are $1.3 million (Q2 2025), $649000.0 (Q4 2024), and $317000.0 (Q3 2024).